Streamline Health Solutions (NASDAQ: STRM), a provider of solutions for healthcare revenue cycle management, reported its second quarter financial results for the period ending July 31, 2024, during an earnings call on August 8, 2024.
The company cited a 21% growth in pro forma SaaS revenue for the first half of fiscal 2024, despite a churn that led to non-renewals totaling $2.8 million in SaaS Annual Contract Value (ACV). The booked SaaS ACV stood at $13.6 million, with $10.7 million already implemented.
Total revenue for the quarter was $4.5 million, a decrease from $5.8 million in the same quarter the previous year. The company's net loss for Q2 2024 was $2.8 million, and it holds $3.5 million in cash and $12.5 million in total debt.
Key Takeaways
- Streamline Health Solutions reported a 21% increase in pro forma SaaS revenue for the first half of fiscal 2024.
- Booked SaaS ACV reached $13.6 million as of July 31, with $10.7 million already implemented.
- The company expects to achieve an adjusted EBITDA breakeven run rate of $15.5 million in the second half of fiscal 2025.
- Total revenue for Q2 2024 was $4.5 million, down from $5.8 million in Q2 2023.
- Net loss for Q2 2024 was $2.8 million, slightly higher than the $2.5 million loss in Q2 2023.
- Operating expenses decreased to $6.7 million from $8.4 million year-over-year.
- The company has $3.5 million in cash and $12.5 million in total debt.
Company Outlook
- Streamline Health anticipates a revenue decline of $300,000 in Q3 2024 but expects recovery to $4.5 million in Q4.
- A significant revenue growth is projected for fiscal 2025, along with improved cash flow.
- The company plans to focus on high-value marketing and social media initiatives to engage more healthcare systems.
- Strategic priorities include a displacement campaign for the eValuator tool, strengthening the Oracle (NYSE:ORCL) partnership, developing new channel partnerships, and maximizing upsells and cross-sells within the existing client base.
Bearish Highlights
- The company experienced churn and non-renewals totaling $2.8 million in SaaS ACV.
- Q2 2024 revenue declined compared to the same quarter last year.
- The net loss for Q2 2024 increased slightly compared to Q2 2023.
Bullish Highlights
- Management expressed optimism for an uptick in bookings in the second half of the year, potentially doubling the first half.
- Positive client feedback suggests eagerness to improve revenue cycles and dissatisfaction with outsourced services post-COVID.
- Successful implementations and upcoming webinars with referenceable clients bolster the Cerner-Oracle partnership.
Misses
- The company missed last year's Q2 revenue, reporting $4.5 million in Q2 2024 versus $5.8 million in Q2 2023.
Q&A Highlights
- Management plans to close deals at a $0.5 million ACV each quarter.
- The company is capitalizing on the market trend of healthcare systems looking to reclaim revenue cycle management in-house.
- The RevID offering, in partnership with Oracle, is undergoing implementations and is expected to have an enterprise-level impact.
Streamline Health Solutions' management, including President and CEO Ben Stilwill and CFO B.J. Reeves, outlined the company's strategic initiatives and financial status during the call. Despite the challenges faced in the first half of fiscal 2024, the company is positioning itself for growth and anticipates a stronger performance in the latter part of the year and into fiscal 2025.
InvestingPro Insights
Streamline Health Solutions (NASDAQ: STRM) has demonstrated resilience in its SaaS revenue despite facing a challenging period. The company's focus on strategic initiatives and partnerships is poised to potentially bolster its performance in the coming quarters. Here are some key insights from InvestingPro that investors might find valuable:
InvestingPro Data highlights that Streamline Health Solutions has a market capitalization of $14.26 million, indicating its size within the healthcare revenue cycle management sector. Despite a challenging environment, the company's gross profit margin remains robust at 51.17% for the last twelve months as of Q1 2023, underscoring its ability to maintain profitability on its services. However, the revenue growth has seen a decline of 11.08% over the last twelve months, which aligns with the company's report of a decrease in total revenue for Q2 2024.
InvestingPro Tips provide further context to the company's financial health and stock performance. Analysts have raised concerns about a potential sales decline in the current year and do not anticipate the company will be profitable this year. The stock's price movements have been quite volatile, and it is currently trading near its 52-week low. Additionally, Streamline Health Solutions does not pay a dividend to shareholders, which may influence investment decisions for those seeking regular income.
It is noteworthy that Streamline Health Solutions has experienced a strong return over the last month, despite the overall negative year-to-date price total return. This could suggest a market reaction to the company's strategic plans or other factors that investors may want to explore further. For a comprehensive analysis, there are additional InvestingPro Tips available for Streamline Health Solutions at https://www.investing.com/pro/STRM, which could provide deeper insights into the company's financials and market position.
Full transcript - Streamline Health Solutions Inc (STRM) Q2 2024:
Operator: Greetings. Welcome to Streamline Health Solutions Second Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] Please note that this conference is being recorded. I would now like to turn the conference over to Jacob Goldberger, Vice President of Finance. Thank you. You may begin.
Jacob Goldberger: Thank you for joining us for the corporate update and financial results review of Streamline Health Solutions for the second quarter of fiscal 2024, which was the three-month period that ended July 31, 2024. As the conference call operator indicated, my name is Jacob Goldberger. Joining me on the call today are Ben Stilwill, President and Chief Executive Officer; and B.J. Reeves, Chief Financial Officer. At the conclusion of today's prepared remarks, we will open the call for a question-and-answer session. If anyone participating on today's call does not have a full text copy of our press release announcing these results, you can retrieve it from the company's website at www.streamlinehealth.net or from numerous financial websites. Before we begin with prepared remarks, we want to be sure we are clear for everyone on the record how certain information which may be provided today as with all of our earnings calls should be viewed. We, therefore, submit for the record the following statement. Statements made on this conference call that are not historical facts are considered to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These are subject to risks, uncertainties, assumptions and other factors that could cause actual results to differ materially from those we may discuss. Please refer to the company's press releases and filings made with the U.S. Securities and Exchange Commission, including our most recent Form 10-K annual report, which is on file with the SEC, for more information about these risks, uncertainties and assumptions and other factors. As always, we are presenting management's current analysis of these items as of today. Participants on this call should take into account these risks when evaluating the topics we will discuss. Please note, Streamline is not undertaking any commitment or obligation to publicly revise any such forward-looking statements made today. On today's call, we will discuss non-GAAP financial measures such as adjusted EBITDA and booked SaaS ACV. Management uses these measures to help provide better insight into our financial performance, however, certain items of income and expense are not included in these measures, so these calculations may differ from those which another entity may utilize in calculating their own non-GAAP measures. To help you compare these amounts on consistent terms, please refer to our website at www.streamlinehealth.net and our earnings release for a reconciliation of such non-GAAP measures to the most comparable GAAP measures. I would now like to turn the call over to Ben Stilwill, President and CEO.
Ben Stilwill: Thank you, Jacob, and good morning, everyone. So far this year, we've significantly expanded the value we provide to the revenue cycle in healthcare. Expansion comes from product enhancements for workforce automation, identifying financial opportunities, both from the clients we have brought online or expanded our impact with, and identifying the next set of clients to partner with us to get paid for the care they provide. As a result, our pro forma SaaS revenue grew 21% during the first six months of fiscal 2024 after excluding the revenues from the client non-renewal we discussed at the end of fiscal '23. During the second quarter, we successfully closed contracts with an aggregate SaaS ACV of $800,000. However, we received notifications of non-renewals and renewals at lower rates for contracts with aggregate value of $2.8 million of SaaS ACV. So, as a result, booked SaaS ACV, which is the annualized contract value for all agreements currently being recognized, as well as bookings that have not been implemented as of July 31, totaled $13.6 million, with $10.7 million already implemented. Due to the reduction in booked SaaS ACV, we now estimate that we will achieve our adjusted EBITDA breakeven run rate of $15.5 million during the second half of fiscal 2025. So, with the significant churn we experienced during the quarter, it's worth visiting how well our service model is working. The clients who terminated or reduced their contracts with us mostly made their decisions due to the lack of resources available to them. In some cases, that is leading them to outsource large parts of their revenue cycle at a higher cost, and others, it leads them to under-staffing these functions and subsequently failing to see potential return. It's an unfortunate dynamic in our market, but also emphasizes the reason our products and service model needs to exist. Our best clients frequently remark how deeply their Streamline counterparts understand their needs and provide them with hands-on education, optimization and insight. Compared to the outsourced model, this helps leaders take back their revenue cycle and keep the crucial knowledge of their system in-house. When a health system chooses to outsource, the vendors they work with are incentivized to not improve the systemic challenges the health system faces. So, we need to continue to invest in the high-quality insights from the data we collect from clients, so that leaders are increasingly aware of the value of owning these outcomes in-house. One specific example, means -- mining client remittance data from 835 reports to help solidify the relationship between the ROI dollars estimated before setting the bill to payers with the actual cash receipts post payer underpayments and denials, which is one of the industry's largest challenges. [This link] (ph), in addition to denials trends, demonstrated coding improvements and collaboration with our CDI departments, create the touchpoints that resonate with higher-level executives as well as the users and managers. In today's budgetary environment, more than ever, health systems have pushed the decisions higher and approval thresholds lower. Our client base contains some of the best health systems in the country and they fully embrace our services model, while continuing to ask for more of these insights. Our client success team would classify them as either blessed for having all the resources they need to succeed or motivated in the sense that they need -- they know they can use our insights to make the improvements that they need. Our challenge and ironically the area for most opportunity is with those health systems who are resource drained or unmotivated by the challenges they face in today's environment. The clients who opted not to renew this quarter are represented here. The clients who did not renew were largely related to outsourcing all or part of their revenue cycle. This outcome is what we're trying to help our clients avoid, because when a health system is forced to outsource their revenue cycle, they lose control of their financial health. The one who did not outsource was due to the [sell of] (ph) facilities, but each of these examples is primarily resource drained. While they may have had the foresight to acquire our solutions, they have to make unfortunate decisions to reduce expense despite positive ROI. So, to help our clients combat the resource drain, we are improving our ability to maintain these relationships long term. We are creating stronger ties with client management, leveraging our results and providing actionable high-level insights to ensure our counterparts and their executives clearly understand our impact and what they stand to lose by not engaging with their Streamline solutions. We're developing formalized best practice manuals for charge reconciliation, building an audit program based on the experience of our successful clients, so that new clients have a great roadmap to success with RevID and eValuator. With eValuator, specifically, we're making our in-house auditing resources available when necessary, generating enough upside that clients can prove their value and maintain control of their HIM departments. We continue to drive tremendous value for our clients. RevID helped a recently go-live identify $0.5 million of mischarges from a single department in just one month of utilization. Not only do we uncover lost revenue, but we help them identify a broken process that would have resulted in significant ongoing leakage. So, in summary, our client success model continues to receive accolades from our clients, and we're confident that we are taking the right steps to ensure retention in a challenging environment. On product innovation, we're working to deliver impactful solutions focused on identifying financial opportunities and providing automated workflows to resolve them. The impact of our AI model, that we talked about at the beginning of the year, continues to create and enhance rules for our eValuator clients exceeding $4 million recently and continues to grow with more rules being deployed and further refined. The model observed coding changes that occurred unrelated to our existing rules. The work started out based on observations within eValuator and is now expanding to coding changes that occurred outside eValuator from other processes or applications both up and downstream from us. We've also successfully developed the powerful risk scoring engine within eValuator and we are looking to bring that to market as an upsell in the near term. Our go-forward eValuator roadmap is focused on identifying additional opportunities for impacts and operational insights, as I highlighted. We are exploring how we can more directly address payer denials, which have increased significantly in the last two years and are a top priority for hospitals. We anticipate having material upgrades to the system for the identification of the denials before the end of fiscal '24. For RevID, the benefits come mostly from our investments in automation. Thousands of charges occur in a hospital daily, so identifying only those that need attention and quickly allowing users to resolve them is paramount. Our recent development remains focused on usability and back-end implementation, while our roadmap includes pattern recognition to automatically assign tasks and improvements to usability. On the growth side of things, during the quarter, I elected to take full ownership of our growth division. While I'm extremely passionate about our clients and products, as hopefully you just heard, nothing is more critical today than us accelerating the rate, which we are bringing in new clients and, therefore, as the leader of this business, I need to live and breathe sales. Over the past decade with the company, I've witnessed a significant shift in the way health systems purchase new revenue cycle solutions. Historically, one-to-one rep and buyer relationships won the day. Today, health systems decisions are made by committees who expect significant data and references. Our relationship may get you in the door, but it cannot close a deal. As a result, we have shifted tactics. Today, the Streamline growth team takes a very analytical approach to our discovery activities, pipeline management and identification of likely buyers. We have motivated hardworking RVPs who are going deep with prospects, helping them understand the significant results their peers have seen within our solutions through historical data and smart projections. We are also hiring more in the regions that we have not covered that fit that persona of the ones that are successful. We've begun to invest more deeply in targeted high-value marketing, expanding on the success we saw with our bootstrap social media strategy, I think many of you saw across sites such as LinkedIn. I expect that together this combination of powerful analytics, sales talent and a renewed focus on marketing will attract more healthcare systems to our client community. But our priorities remain: the first, a displacement campaign related to an existing offering in eValuator space where we believe our tool delivers better results at a lower cost; two, a continued emphasis on our Oracle partnership, which continues to aggressively push RevID; and three, the development of a new and effective channel partner; four, and the last one, beyond new client sales, we can more than double our existing ARR through upsells and cross-sells within our existing client base. We've seen success in each of these areas. We've had a number of positive discovery activities as a result of our displacement campaign, and with the right pricing strategy, I'm confident we will see a win from that channel in this fiscal year. We've had several successful Oracle go-lives already in fiscal '24 with more in our backlog and Oracle has been instrumental in a portion of our new bookings and our marketing efforts. We've been presenting jointly with our sales team to additional prospects and at trade shows and continue to see an uptick in the number of prospects Oracle is introducing us to. We've also had successful upsells during the quarter and are working to expand our upsell potential with additional eValuator functionality. Our first enterprise clients, one who added RevID, another who added eValuator, will both go live with their respective new Streamline solutions during the second half of this year. We'll be excited to share success stories obviously once we've had some time to work with these clients after their go-lives. From a sales operation standpoint, we're arming our sales force with enhanced messaging to match with industry priorities and better explain the overall financial impact of our solutions for all prospects to align with the priorities of the C-suite leadership and with VP and Director level counterparts. In some cases, clients have brought up our solutions at peer roundtables and we're looking to encourage more peer-to-peer activities in our user base. So, healthcare systems need to be able to succeed in the revenue cycle so that they can get paid for the care they provide. We believe it is our duty to develop the products and provide the insights so that they can succeed. And so, with that, I'd like to turn the call over to our CFO, B.J. Reeves.
B.J. Reeves: Thank you, Ben, and good morning, everybody. As Ben mentioned, our booked SaaS ACV as of July 31, 2024, totaled $13.6 million, and we continue to expect that we can generate persistent positive adjusted EBITDA above $15.5 million SaaS ARR run rate. Currently, $10.7 million of our booked SaaS ACV is implemented and we anticipate we will successfully implement and achieve that $15.5 million ARR run rate during the second half of fiscal 2025. As Ben noted, this adjusted breakeven timing expectation is the result of unexpected churn during this fiscal quarter. We expect to continue to recognize revenue from more than half of the $2.8 million of non-renewal contracts through November of 2024. Total revenue for the second quarter of fiscal 2024 was $4.5 million as compared to $5.8 million during the second quarter of fiscal 2023. Revenue for the first six months of fiscal 2024 was $8.8 million as compared to $11.1 million for the same period of fiscal 2023. The change in total revenue for both the three- and six-month periods was attributable to previously announced client non-renewals, offset by the successful implementations of new SaaS contracts. SaaS revenue totaled $3 million and $3.5 million, representing 67% and 60% of total revenues during the second quarters of fiscal 2024 and 2023, respectively. For the first six months of fiscal 2024, SaaS revenue totaled $5.8 million, 66% of total revenue, compared to $6.7 million or 60% of total revenue during that same period of fiscal 2023. As previously reported, the company had a SaaS contract which did not renew toward the end of its fiscal -- its 2023 fiscal year. On a pro forma basis, excluding the revenue recognized from that client, SaaS revenue grew 19% in the second quarter of fiscal 2024 and 21% in the first six months of fiscal 2024 versus the same respective periods for fiscal 2023. As a result of the client non-renewals and reductions Ben mentioned, we currently anticipate that third quarter fiscal 2024 total revenue will decline sequentially by approximately $300,000, but will return to approximately $4.5 million of total revenue in the fourth quarter of fiscal 2024 as we successfully implement the existing contracts, and expect revenue to grow sequentially in fiscal 2025. Total operating expense during the most recent quarter was $6.7 million compared to $8.4 million for the second quarter of fiscal 2023. During the first six months of 2024, operating expense totaled $13.3 million as compared to $16.7 million during the first half of 2023. The lower overall operating expense for the three and six months period was the result of the company's previously announced strategic restructuring and was primarily reported in SG&A and R&D. We also saw lower costs associated with our professional fees and software licenses in line with lower overall revenue from that portion of our business. We do not anticipate significant increases in operating expenses for the duration of the fiscal year or in fiscal 2025. We continue to make investments to improve our technology, including the development of enhancements such as the My eValuator update, continuing development and expansion of applications for the AI technology that we have leveraged to generate additional content and improvements related to automation and usability for the RevID solution. Second quarter fiscal 2024 net loss totaled $2.8 million or a loss of $0.05 per share, compared to a loss of $2.5 million or a loss of $0.04 per share in the second quarter of fiscal 2023. The more significant net loss during the recent quarter, despite improved operating costs, was primarily the result of higher non-cash interest expense associated with the private placement notes issued during the first quarter of this fiscal year, as well as an approximate $100,000 valuation adjustment expense in this recent second quarter of fiscal 2024, as compared to $359,000 of valuation adjustment income during our second quarter of fiscal 2023. For the six months ended July 31, 2024, total net loss was $5.5 million, or a loss of $0.09 per share, as compared to $5.4 million or a loss of $0.10 per share for the same six-month period of fiscal 2023. The relatively static net loss despite lower revenue was the result of the significant cost savings that I previously mentioned, offset by the same non-cash interest and valuation expenses that impacted the three-month period. Adjusted EBITDA for the second quarter of fiscal 2024 was a loss of $300,000, compared to a loss of $900,000 during the second quarter of fiscal 2023. For the six months ended July 31, 2024, our adjusted EBITDA was a loss of $1 million, compared to a loss of $2.2 million for the same period of fiscal 2023. The significant improvement of adjusted EBITDA for the three- and six-month period is the result of the company's focus on the growth of its SaaS revenue solutions, as well as significant cost savings achieved through the previously announced strategic restructuring. Moving to the balance sheet. As of July 31, 2024, we had $3.5 million of cash on hand compared to $3.2 million at January 31, 2024. As a reminder, during the first quarter, we executed private placements for gross proceeds of $4.5 million. Our total debt, including senior debt loan and notes resulting from that private placement, was $12.5 million, and we had no balance outstanding on our $2 million revolving credit facility as of July 31, 2024. Looking forward, as we continue to execute new bookings in fiscal 2024, we anticipate significant revenue growth in fiscal '25 and the achievement of persistent adjusted EBITDA profitability and significant improvement in our use of cash for operations throughout 2025. That concludes our review. Operator, please begin the question-and-answer session.
Operator: Thank you. We will now be conducting a question-and-answer session. [Operator Instructions] Our first questions come from the line of Matt Hewitt with Craig-Hallum. Please proceed with your questions.
Matt Hewitt: Good morning, and thanks for taking the questions. Maybe digging in a little bit on the market itself, what are you hearing from customers? I know that procedure volumes seem to be improving a little bit, but it's not to say that it's broad based or that all hospitals or health systems are in recovery mode yet. So, any details on what you're hearing from customers would be helpful?
Ben Stilwill: Yeah. Thanks for the question, Matt. So, what we've heard is that they are making material investments into whether it's expanding their physical footprints or new service lines to accommodate the patient volumes that they're seeing. But they're still struggling with the -- what I'll say is that the revenue cycle side of things and sort of the payer dynamics, you've heard a lot about managed care, et cetera. And so, they're still trying to navigate those payer dynamics and use tools to do that.
Matt Hewitt: Got it. And then, shifting gears a little bit. So, over the past couple of years, you've kind of created or added a number of enhancements to your software. What gives you confidence now that you're kind of turning the corner here in that? As we look to '25, you mentioned sequential growth next year. What gives you the confidence that you can see those types of returns?
Ben Stilwill: Yeah. I think our products are definitely better than the competition as far as a standalone technology and then pair that with our service model. We do have opportunities to add additional modules to our existing software as well. And people are very ecstatic about some of those opportunities, the current clients that we have. So, if we extrapolate that to the broader market, we do think that we have a lot of opportunity there.
Matt Hewitt: Got it. All right. Thank you.
Operator: Thank you. Our next questions come from the line of Michael Potter with Monarch Capital. Please proceed with your questions.
Michael Potter: Hey, Ben. I was hoping that you can give us a little bit more detail around the pipeline that we currently see. And how late is that pipeline in regards to, are we expecting significant movement in that pipeline being converted into contracts over the next quarter or two?
Ben Stilwill: Sure. So, we were not happy with the first half bookings number, for sure. I think when I stepped into the role and I looked at the opportunities that we have had out there, the ones that we're currently using our reps to close, we should see a good uptick in the second half of the year just from the opportunities that are out there, not including some of the initiatives that I kind of mentioned during my remarks.
Michael Potter: Okay. So, you're expecting some significant closings before the end of the fiscal year?
Ben Stilwill: That's correct. Yeah, we have a good line of sight on some deals that will actually close before the end of the fiscal year.
Michael Potter: Can you give us a dollar value of the current pipeline?
Ben Stilwill: We're not currently giving guidance on the total value of the pipeline, but I would say that if you look at the first half bookings, we're looking at more than double that in the second half. As far as the total overall pipeline, it is pretty heavily weighted in the middle of it. So, we expect to still get back on track to have a couple of deals a quarter closing at that $0.5 million ACV.
Michael Potter: Okay. And then, can we touch upon a little bit on the value proposition to our customers? Obviously, we hit a bump in the road for extenuating circumstances, it seems, but what are you hearing from our existing customer base? Are we exceeding their expectations? Are they seeing the cost savings? Are they seeing reduction in compliance costs? What kind of feedback are you getting from our current customer base?
Ben Stilwill: Yeah. So, from our current client base, they're very -- by and large, like I said, they are motivated to turn around their revenue cycle. Our best clients are very resource positive, so they can use the most of our solutions. I would refer to some of our prospect conversations as being very interesting right now because they, during COVID or shortly after, outsourced some of these to other vendors, and they're now disenfranchised by that outcome. They've realized how much they lost by doing that. And so, one of our marketing pushes in the near future is going to be take back the revenue cycle, because people realize, hey, I need to bring this back in-house and I need to enable my troops to be able to find the financial impact.
Michael Potter: Okay. And just one other question, the Cerner-Oracle relationship, you said we have several implementations on the platform at this point and several more in our pipeline. How is that progressing? And how is that different? I know that's the RevID offering. How is that different than how our go-to-market with eValuator?
Ben Stilwill: Yeah. So, we had a couple that went live at the beginning of the year who have now seen significant impact. They've been referenceable clients, which is obviously a huge thing in this selling process. As of late, they are signing up to do a webinar very soon. So, they're very positive. And then, we have a couple in the pipeline who are -- sorry, in the implementation backlog, who are well on their way. Some of it is tied to Oracle's upgrade of their accounting system, but some of it is just going through the project process. As we get more of those, it's a very connected community. And so, we anticipate that they'll be very vocal with their counterparts. But Oracle themselves has committed to the relationship. They are making active introductions and working with us. How that compares to eValuator? It is a little bit more complex sale, sometimes viewed as a -- it can be more impactful at an enterprise level, so you have to bring in more departments versus eValuator's, can sometimes be viewed as something that helps a specific department. And so, maybe you can have less people involved in the process.
Michael Potter: Okay, great. All right. Thanks, Ben, for the color. Good luck in the second half of the year.
Ben Stilwill: Thank you, Mike.
Operator: Thank you. We have reached the end of our question-and-answer session. I would now like to hand the call back over to management for closing remarks.
Jacob Goldberger: Thank you all for joining us today, and thank you for your continued support of Streamline Health Solutions. We look forward to speaking with you again when we will discuss our third quarter financial results. Thank you, and good day.
Operator: Thank you. This does conclude today's teleconference. We appreciate your participation. You may disconnect your lines at this time. Enjoy the rest of your day.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.